The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S. production ahead of ...

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

The Detroit automaker's net income slid 6.6% in the first quarter on weaker sales of highly profitable trucks and SUVs. The company expects to save an additional $1.2 billion from automation, AI and ...

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house U.S. site to make the blockbuster ...

Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...